Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
Pharmaceutical
Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space.
How has the company achieved this — on the R&D and patient access side — and what is the company doing to help the remaining patients? Vertex’s Andrew Wilfin, Senior Country Medical Director, UK and Ireland, took part in a Q&A with The Pharma Letter to reveal all. 7 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial intelligence (AI) intended to support a regulatory decision about a drug or biological product’s safety, effectiveness or quality. 7 January 2025
Pharmaceutical
Sentynl Therapeutics, wholly owned by Zydus Lifesciences, has announced that the US Food and Drug Administration has accepted its New Drug Application for CUTX-101, a potential first treatment for Menkes disease. The application has been granted priority review, with a target action date set for June 30, 2025. 7 January 2025
All news
Pharmaceutical
A firm in Massachusetts, USA, has won approval for a new kind of medicine, a phosphate absorption blocker, which will be used to treat certain people with chronic kidney disease (CKD). 18 October 2023
Pharmaceutical
Swiss pharma giant Roche has announced results from the primary analysis of the Phase III ALINA study. 18 October 2023
Pharmaceutical
October marks the annual Rett Syndrome Awareness Month, a time to examine the support and research being afforded to advance pharmacological treatments for this rare condition. 18 October 2023
Pharmaceutical
Despite statements from international pharmaceutical companies about the suspension of new clinical trials in Russia after February 24, 2022 invasion of Ukraine, the Anglo-Swedish drug major AstraZeneca will conduct a study of a new drug for the prevention of COVID-19 in Russia, reports The Pharma Letter’s local correspondent. 18 October 2023
Pharmaceutical
A formal disclosure from Aldeyra Therapeutics, suggesting a potential rejection from the US Food and Drug Administration, has stripped around 70% from the firm’s share price. 17 October 2023
Pharmaceutical
US healthcare conglomerate Johnson & Johnson has announced results for third-quarter 2023. 17 October 2023
Pharmaceutical
Analysis of American prescribing trends made available by health tech pioneer DrFirst show a six-fold increase in prescriptions written for popular weight loss drug Wegovy (semaglutide) between December 2022 and June 2023. 17 October 2023
Pharmaceutical
Swedish enzyme specialist Hansa Biopharma has announced results from an extended pooled analysis of the 17-HMedIdeS-14 study, testing the antibody-cleaving enzyme imlifidase. 17 October 2023
Pharmaceutical
With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market is expected to grow at a compound annual growth rate (CAGR) of 5.2% from $31.9 billion in 2022 to $53 billion in 2032 across the seven major markets. 17 October 2023
Pharmaceutical
Italian drugmaker Recordati has appointed Milan Zdravkovic as its executive vice president of Research & Development (R&D). 17 October 2023
Pharmaceutical
Danish company Novo Nordisk has agreed to acquire ocedurenone - a drug in development for uncontrolled hypertension with potential application in cardiovascular and kidney disease - from Singapore biotech KBP Biosciences for up to $1.3 billion. 16 October 2023
Pharmaceutical
If Ireland’s people were not already somewhat pessimistic on Monday following the country’s exit from the Rugby World Cup, they have further reason for gloom, according to the Irish Pharmaceutical Healthcare Association (IPHA). 16 October 2023
Pharmaceutical
US pharma major Eli Lilly has released detailed results from the Phase III SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. 16 October 2023
Pharmaceutical
Britain’s largest drugmaker, AstraZeneca, has been granted a Priority Review for its bid to broaden the label for Tagrisso (osimertinib) in the USA. 16 October 2023
Pharmaceutical
The US Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), on Friday announced it has selected initial next-generation vaccine candidates and more than $500 million in awards for Project NextGen. 16 October 2023
Pharmaceutical
At its October monthly meeting, the European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval. 14 October 2023
Pharmaceutical
Etrasimod, Pfizer’s oral S1P receptor modulator, has won approval from the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative colitis (UC). 13 October 2023
Pharmaceutical
USA-based CNS disease specialist Supernus Pharmaceuticals has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD). 13 October 2023
Pharmaceutical
New data from real-world evidence studies from Anglo-Swedish pharma major AstraZeneca highlight that immunocompromized (IC) individuals continue to face significant and disproportionate burdens from COVID-19. 13 October 2023
Pharmaceutical
US pharma giant Pfizer’s shares dropped 2.5% to close the regular session at $32.11, and fell a further 3.7% to $30.92 in after-hours trading, after it announced significantly changed financial guidance and updated on its government contracts for coronavirus products. 13 October 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze